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Abstract 
Background: Most medicines are imported for health service practices in Afghanistan. A major concern for patients 
and practitioners in Kabul is the wide brand assortment and price range choices for the same drug. Ceftriaxone 
sodium is a broadly used antibiotic for infections caused by certain types of gram-positive and gram-negative bac-
teria. It is available in Kabul in a range of brands and prices. The objective of this study was to assess the relationship 
between cost/brand name and efficacy of this antibiotic.
Methods: 40 brands of ceftriaxone, obtained from Kabul’s main pharmacy, were derived from 12 countries includ-
ing Pakistan, Turkey, India, and China. Ten samples/brand were tested for efficacy by the minimal bactericidal con-
centration assay against a sensitive strain of Staphylococcus aureus according to the Clinical Institute and Laboratory 
Standards Protocols. Efficacy data were obtained by inoculating suspensions of S. aureus grown in Mueller–Hinton 
medium with various concentrations (6.25–800 mcg/ml) of each brand followed by incubation at 37 °C for 18–24 h. 
Aliquots of inoculated cultures were transferred to agar plates, incubated at 37 °C for 18–24 h and visible colonies 
counted. Results were analyzed using ANOVA, Student’s t test, and Pearson correlation by SPSS 19. A p value ≤ 0.05 
was considered statistically significant.
Results: Ceftriaxone sodium price varied from 20–270 Afghanis/brand (average price = 69.80 Afghanis/brand). Of 
the 40 brands tested, 10 (25 %) were not registered with the General Directorate of Pharmaceutical Affairs of the Min-
istry of Public Health in Afghanistan. More importantly, we observed no statistically significant difference in efficacy 
against S. aureus among these brands (p = 0.59).
Conclusions: Our study showed no significant correlation among price, brand, and efficacy of ceftriaxone sodium 
against S. aureus, an important consideration when treating S. aureus infection in Afghanistan and elsewhere. Differ-
ences in brand prices are likely due to other factors including manufacturing and exportation costs, regulations of 
good manufacturing practice and seller’s profit ceiling and patient preferences. Based on our results, we suggest that 
further chemical and clinical studies of ceftriaxone sodium brands are warranted and recommend that physicians 
consider alternative cost-effective generic brands in patient prescriptions.
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Background
Efficacy, availability and cost of medicines are a serious 
concern in health care systems globally. Substandard and 
counterfeit clinically used drugs that compromise the 
health of patients continue to overwhelm markets world-
wide and is especially a problem in developing countries 
[1]. Lack of rigorous quality assurance measures in many 
developing countries including Afghanistan exacerbate 
the problem and lead to increased incidences of many 
Open Access
BMC Research Notes
*Correspondence:  hm_naimi@yahoo.com 
Department of Microbiology, Faculty of Pharmacy, Kabul University, Jamal 
Meena Street, Kabul, Afghanistan
Page 2 of 6Naimi et al. BMC Res Notes  (2016) 9:86 
diseases with devastating consequences on health care 
infrastructures.
Quality, efficacy and safety must be primary con-
cerns for health care systems world-wide [2]. Yet, con-
taminating toxic chemical substances, inadequate and 
inconsistent drug supply mechanisms, and lower-active 
ingredients doses, are all factors associated with counter-
feit/substandard treatments that diminish quality [3] and 
are risk factors for anti-microbial resistance, organ fail-
ure, and increased mortality rates globally [4, 5].
Afghanistan depends on imports of nearly all medi-
cines since its pharmaceutical industries lack the capac-
ity to adequately meet the population’s health care needs. 
According to the World Health Organization [6], the 
Ministry of Public Health of Afghanistan is not equipped 
to effectively control the quality of medical drugs enter-
ing the market as regular and periodic quality-control 
mechanisms necessary to do so are lacking. For exam-
ple, well-equipped laboratories and well-trained human 
resources are essential for efficient registration and 
licensing of imports. Afghanistan’s national medicines 
quality control laboratory operates under challenging 
conditions in dilapidated structures, which are not inter-
nationally accredited. The UK Department for Inter-
national Development states that the amount of both 
donated and imported medicines by private companies 
has increased dramatically since 2002 in Afghanistan. 
Furthermore, the amount of illegally imported medicines 
has risen in the private sector, which further compounds 
the problem in an already substandard health care situa-
tion [7].
Most private importers in Afghanistan who procure 
medical drugs are located in Kabul city. Considerable dif-
ference in prices of various brands of the same drug in 
the city has raised the question in the scientific commu-
nity of whether price equates quality. According to the 
Afghanistan National Medicine Law any registered inter-
nal or external company can import registered medi-
cines without considering price differential ranges among 
brands for the same item [6]. Given the large number 
of clinically used drugs and the increasingly heavy traf-
ficking of these substances, it is a daunting task for the 
Ministry of Public Health to identify imports and control 
efficacy, safety, quality, price and stem the flow of coun-
terfeit medicines in Afghanistan.
One of the main classes of antibiotics used widely in 
clinics internationally are the third-generation cephalo-
sporins which are effective against certain gram-positive 
and gram negative bacteria. These antibiotics are used to 
treat a wide range of infectious diseases including pneu-
monia, urinary tract infections, meningitis, peritonitis, 
biliary infections, surgical prophylaxis, prophylaxis of 
meningitis and gonococcal infections [8]. Ceftriaxone 
sodium, a member of the third generation cephalospor-
ins, is a drug of choice in the clinical setting to treat such 
infections because of increased potency and longer half-
life [8].
Thus far, comprehensive studies have not been carried 
out in Afghanistan to assess the relationship between 
efficacy and price among the many brands of ceftriax-
one sold in Kabul pharmacies. The main objective of this 
study was to determine whether comparative in  vitro 
efficacy contributed to variation in prices in forty differ-
ent brands of ceftriaxone available in Kabul to promote 
rational use of cost-effective brands of the drugs.
Methods
This study was conducted in the microbiology laboratory 
of the faculty of pharmacy of Kabul University within a 
period of 6 months. A selection of forty different brands 
of ceftriaxone sodium was purchased as 1 g/vial/sample 
from the Kabul private medicine market (Kabul phar-
macy), the main wholesaler market of medicines in Kabul 
city and a distributor of medical drugs throughout the 
country. This drug is only available as an injectable. Ten 
samples of each brand of ceftriaxone sodium was tested 
to compare efficacy with samples of others brands in the 
group. Each brand was numerically coded to obscure 
name and price to maintain a blind study. All brands were 
purchased at the community wholesaler’s fixed rates/
drug. All drugs were stored at 25–30 °C until experimen-
tal analyses. Drugs that had reached the expiration date 
were not used in this study.
A susceptible strain of Staphylococcus aureus (S. 
aureus; American Type Culture Collection #29213) was 
used to determine comparative in  vitro anti-bacterial 
activity of each sample/drug/brand using the minimal 
bactericidal concentration (MBC) of each brand toward 
S. aureus according to the Protocols of the Clinical Labo-
ratory Standards Institute [9]. This S. aureus (ATCC 292) 
strain was used in the study because it showed suscep-
tibility to ceftriaxone and its genotype was confirmed as 
wild-type by the French Medical Institute in Kabul. In 
addition, ceftriaxone has been effectively used to treat 
various clinical conditions caused by S. aureus.
All culture media were prepared according to the man-
ufacturer’s (Difco) instructions and all S. aureus cultures 
were maintained in identical growth conditions.
Briefly, we cultured −20  °C frozen S. aureus stock on 
Tryptose blood agar plates (Difco) at 37 °C for 18–24 h. 
After this time, 1–2 separate colonies of S. aureus were 
transferred into 5  ml normal saline to make a turbidity 
of 1 McFarland bacteria suspension. We then used 10 µl 
of this suspension to inoculate test tubes containing 
2  ml Muller Hinton broth (Difco) mixed with a ceftri-
axon sample with doses ranging from 6.25 to 800 mcg/
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ml drug sample/brand and cultures subsequently incu-
bated at 37 °C for 18–24 h. Positive Control samples were 
not treated with ceftriaxone while negative control sam-
ples did not contain bacterial suspension. 10 μl of drug-
inoculated S. aureus cultures without visible growth were 
next streaked onto Muller Hinton Agar (Difco) plates, pH 
7.2 and grown for an additional 24 h at 37 °C. Following 
incubation, the plates were examined for formation of 
S. aureus colonies. The concentration of ceftriaxon that 
produced no growth was recorded as the MBC.
S. aureus drug comparative efficacy measurements 
were obtained from the average MBC of each drug brand 
using ANOVA test and the statistical program SPSS 19. 
The relationship between efficacy and prices was deter-
mined by the Pearson’s correlation coefficient test and 
differences between price and efficacy of registered and 
non-registered brands compared by Student’s t-test. A p 
value ≤ 0.05 was considered statistically significant (drug 
brands: n = 40; sample replicates: 10 samples/drug brand; 
technical replicates: 10/samples; total MBC assays: 400).
Results
In this study, a total of 40 different brands of ceftriaxone 
were obtained from Kabul’s main pharmacy to test price 
versus efficacy. Prices among the samples varied from 20 
Afghanis (~0.35 USD) to 270 Afghanis (~4.69 USD) with 
an average price of 69.80 and a median of 57.50 Afghanis 
(STD  ±  49.53). The ceftriaxone brands were manufac-
tured in many countries, with most from Pakistan (19 
companies), Turkey (5 companies), Korea (3 companies), 
China (3 companies), and India (3 companies). Others 
among the group represented by one brand each were 
manufactured in Canada, Germany, Taiwan, Indonesia, 
Iran, Switzerland and the United Arabic Emirates (Fig. 1).
We found that all of the ceftriaxone brands were 
packed according to international regulation standards 
and each vial contained distilled water for solubilizing 
the lyophilized drug. All vials were also labelled with the 
manufacturers’ name, batch number, date of manufac-
ture, expiration date, and other specifications related to 
manufacturing.
Using ANOVA test we showed that the average Mini-
mal Bactericidal Concentration for all brands against 
a sensitive strain of wild type S. aureus was 402.01  μg/
ml (95  % CI, 373.13–430.90). The average MBC among 
brands ranged between 255.56 and 622.22  μg/ml but 
these differences were not statistically significant 
(p = 0.59) (Fig. 2).
Pearson test showed a poor correlation between price 
and efficacy among the various brands of ceftriaxone. 
A rise in the price by one Afs and a decrease in MBC 
of ~0.069 μg/ml was observed, but this was not statisti-
cally significant (r = −0.069, p = 0.189) (Fig. 3).
Each brand of the ceftriaxone drug was also graded 
according to their respective MBC from lowest to high-
est values (1–40) versus price, however, our data again 
showed that there was no significant relationship 
between price and efficacy (Fig. 4).
Finally, we separated registered from unregistered 


























Fig. 1 The graph shows number of brands of ceftriaxone tested and countries of manufacture. The X-axis indicates the various countries that the 
antibiotics were obtained from and the Y-axis, number of brands tested for ceftriaxone from those countries with the exact numbers given above 
each bar
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Student’s t test. We found that the average MBC for reg-
istered brands were 398.89  μg/ml while unregistered 
brands had an average MBC of 411.39 μg/ml (p = 0.71). 
The average price for ceftriaxone brands that were reg-
istered was 73.90 Afghanis versus 75.50 Afghanis for 
unregistered brands (p = 0.78). In both cases the results 
were not statistically significant.
Discussion
Affordability of medical treatment is a key factor in 
patient health care globally and is especially true for 
those living in socioeconomically disadvantaged envi-
ronments. The focus of this study was to test efficacy of 
several brands of Ceftriaxone sodium antibiotics as they 
relate to price using the MBC test for efficacy. We have 
not measured impurities in these samples and additional 
chemical tests will be required to do so. The results from 
our work show no significant differences in efficacy and 
prices of various ceftriaxone brands circulating in Kabul’s 
main Pharmacy chain. The findings are important to 
medical practice globally and indicate that clinicians 
should be prescribing lower cost ceftriaxone.
We also show that broth dilution antimicrobial suscep-
tibility testing using the MBC method is an effective way 
to identify counterfeit drugs and substandard ones with 
diluted active ingredients [9]. According to the United 
States Pharmacopeia, the quantity of Ceftriaxone sodium 
antibiotics in labels must be in the range of 90–115  % 
[10]. All 40 brands of ceftriaxone used in this study were 
labelled with the active ingredient within this range and 
all showed the same efficacy against S. aureus regardless 
of price.
This study to show efficacy versus price is the first to be 
carried out in Afghanistan. Most of the brands included 
in our analyses were not studied before and none were 
tested for efficacy using the MBC assay. Our results how-
ever, validated other published work, which tested 3–6 of 
the brands used in our study by other methods, that the 
price of medically used drugs are not necessarily a deter-
mining factor for quality [11, 12].
One study conducted in Afghanistan of 11 differ-
ent types of drugs available in public and private sector, 
including two brands of ceftriaxone found that 9  % of 
the drugs tested by chemical assays were substandard 
but ceftriaxone was not among the substandard group 
(13). This study concluded that the majority of drugs 
in Afghanistan are not counterfeit or substandard. The 
Pakistan cost-effective analysis study done with the six 
brands of ceftriaxone also showed similar in vitro activity 
of these brands against several gram negative and gram 
positive bacteria including S. aureus [11]. Assessment of 
33 brands of ceftriaxone quality, available in Pakistan, by 
high-pressure liquid chromatography (HPLC) indicated 
that  ~15.62  % ceftriaxone brands did not meet speci-
fication standards although none of the 96 samples of 
drugs tested were counterfeit [12]. In addition, studies in 
Nepal on the in vitro activity of three brands of ceftriax-
one against various bacteria isolates from clinics in the 
Fig. 2 The graph shows the average minimal bactericidal concentration (MBC) of different brands of ceftriaxone against S. aureus in µg/ml. The 
X-axis indicates various brands of ceftriaxone and the Y-axis, the average of minimal bactericidal concentration/ml for each brand with minimum 
and maximum values indicated with error bars
Page 5 of 6Naimi et al. BMC Res Notes  (2016) 9:86 
country indicated that the minimal inhibitory concen-
tration and biological activity among them were not the 
same and in one brand, MIC was higher by at least two 
fold suggesting this brand had less in vitro activity against 
isolates tested [14].
Our study which was done to test efficacy versus price 
of a much larger selection of ceftriaxone brands using 
biological methods argue against this finding and addi-
tionally showed that there was no difference in price ver-
sus efficacy among brands.
The results from our work may serve as a deterrent to 
both the manufacturer and import of substandard and 
counterfeit injectable antibiotics in Afghanistan, which 
will lower the risk of severe side effects caused by these 
drugs to patients.
We suggest that the differences in price for ceftriaxone 
are related to other factors that do not directly contrib-
ute to efficacy or quality of the antibiotic. Prices were 
found to be highest for drugs manufactured by large 
internationally known pharmaceutical companies, are 
in the medium-ranges when obtained from large local 
or regionally known generic pharmaceutical companies, 
and in the low-priced range from generic companies that 
sell drugs in regional markets only. Lack of monitoring 
and control of price rates of medical products in Afghan-





















Price in Afs 
P= 0.189 
Fig. 3 The graph shows correlation between price and MBC of each brands. The X-axis indicates price and the Y-axis the average minimal bacteri-
















Order of brands according to MBC for lowest to highest 
Fig. 4 The graph shows the grading of different brands of ceftriaxone according to the MBC obtained versus price. The X-axis indicates the minimal 
bactericidal concentration of all brands from lowest to highest and the Y-axis, the price for each brand
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in the country as importers and sellers purchase products 
with different prices. Thus, manufacturing cost, location 
of the company, as well as import and distribution costs 
may all contribute to fluctuations in price of the drugs 
rather than their potency. In addition, we cannot rule out 
the influence of patient preferences for specific brands 
and the general belief that higher prices means better 
quality as other contributing factors to price variations 
among these antibiotic brands.
Conclusions
Our study shows that there is no relationship between 
cost and efficacy of various brands of ceftriaxone anti-
biotics in Kabul. While further studies using chemical 
assays for quality control tests including impurities and 
clinical trials are necessary to compare in vivo efficacy of 
the various ceftriaxone brands, based on our results, we 
recommend that physicians and pharmacists consider 
cheaper ceftriaxone alternatives for patients.
Authors’ contributions
HMN has made substantial contributions to the conception and design of 
the study, analysis and interpretation of data and has given final approval to 
submit the manuscript for published. HR was involved in drafting manuscript 
and design of experiments to ensure accuracy and integrity of results. MHR 
was involved in the culture of microorganisms and preparation of antibi-
otic dilutions for efficacy measurements. HY statistically analyzed the data, 
participated in bacterial growth and sample collection. All authors read and 
approved the final manuscript.
Acknowledgements
This article and author’s participation in the Afghanistan Biosciences Fellow-
ship Program is sponsored by the U.S. government, Cooperative Biological 
Engagement Program with support from CRDF Global. The content of the 
information does not necessarily reflect the position or the policy of the fed-
eral government, and no official endorsement should be inferred. We thank 
the Research Department of Ministry of Higher Education of Afghanistan 
and the World Bank’s Strengthening Higher Education Program authorities 
for financial support; Dr. Tariq Mahmood from the French Medical Institute in 
Kabul, for providing us the standard strains of Staphylococcus aureus. Many 
thanks as well to CRDF Global staff Dane Button, Jeff Skowera, and Megan 
Tribble for supporting this program and to the CRDF Global consultant Dr. 
Joyce Tombran-Tink from Penn State University College of Medicine for assist-
ing us in editing the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 22 December 2015   Accepted: 2 February 2016
References
 1. World Health Organization. Substandard and counterfeit medicines, Fact 
sheet, No. 275. Geneva: WHO; 2003.
 2. Videau JY. Making medicines safe. Bull WHO. pp. 79–87.
 3. Julian M, Philip S. Counterfeit medicines in less developed countries. 
London: International Policy Network; 2006. p. 3–7.
 4. Alubo SO. Death for sale: a study of drug poisoning in Nigeria. Soc Sci 
Med. 1994;38:97–103.
 5. Wondemagegnehu E. Counterfeit and substandard drugs in Myanmar 
and Vietnam. Report of a study carried out in cooperation with the gov-
ernments of Myanmar and Vietnam. WHO: Geneva; WHO/EDM/QSM/99.3. 
pp. 3–8.
 6. Afghanstan National medicine policy, Islamic government of Afghanistan, 
MoPH. 2003. http://www.who.int/selection_medicines/country_lists/
AFG_NMP_03.pdf.
 7. Report of sampling, testing and quality control survey in Afghanistan, 
MoPH. 2010. http://gdpa.gov.af/Content/Media/Documents/MedSam-
pli_Test_QuantitSurvey_D_2011043010201483446131458322570.pdf.
 8. Ceftriaxon. British National formulary 66th ed, 2014. pp. 360–364.
 9. Arthur L, Barry et al. Methods for determining bactericidal activity of 
antimicrobial agents; approved guideline. CLSI. 1999.
 10. Craig Brater D, et al. United States Pharmacopeia 29 NF 24. Rockville: 
United States Pharmacopeial Convention. 2006. 1:440.
 11. Baqir Naqvi S, et al. Cost effective analysis of different brands of ceftriax-
one available in Karachi, Pakistan. Pak J Pharm. 2008;25:13–9.
 12. Ali Obaid. Quality of ceftriaxone in Pakistan: reality and resonance. Pak J 
Pharm Sci. 2009;22:220–9.
 13. Report of Afghanistan medicines sampling and testing—a quantitative 
survey, MoPH. 2011. pp. 9–42.
 14. Thapa B, Mahat K. In-vitro activity of three brands of ceftriaxone against 
different clinical isolates. J Nepal Med Assoc. 2010;49:225–7.
